vs
Side-by-side financial comparison of Cue Biopharma, Inc. (CUE) and UNITY BANCORP INC (UNTY). Click either name above to swap in a different company.
UNITY BANCORP INC is the larger business by last-quarter revenue ($35.3M vs $21.9M, roughly 1.6× Cue Biopharma, Inc.). UNITY BANCORP INC runs the higher net margin — 43.9% vs 7.2%, a 36.6% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs 24.2%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs 17.5%).
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
Unity Bancorp Inc is a New Jersey-headquartered financial holding company operating Unity Bank. It offers a full range of commercial and retail banking services including business loans, deposit products, mortgage services, and personal banking solutions, primarily serving small and medium-sized enterprises and individual consumers across local communities in New Jersey and eastern Pennsylvania.
CUE vs UNTY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.9M | $35.3M |
| Net Profit | $1.6M | $15.5M |
| Gross Margin | — | — |
| Operating Margin | 9.0% | 55.8% |
| Net Margin | 7.2% | 43.9% |
| Revenue YoY | 1292.3% | 24.2% |
| Net Profit YoY | 116.7% | 34.5% |
| EPS (diluted) | $0.05 | $1.52 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.9M | $35.3M | ||
| Q3 25 | $2.1M | $32.8M | ||
| Q2 25 | $3.0M | $34.4M | ||
| Q1 25 | $421.0K | $29.4M | ||
| Q4 24 | $1.6M | $28.4M | ||
| Q3 24 | $3.3M | $27.7M | ||
| Q2 24 | $2.7M | $25.5M | ||
| Q1 24 | $1.7M | $25.6M |
| Q4 25 | $1.6M | $15.5M | ||
| Q3 25 | $-7.4M | $14.4M | ||
| Q2 25 | $-8.5M | $16.5M | ||
| Q1 25 | $-12.3M | $11.6M | ||
| Q4 24 | — | $11.5M | ||
| Q3 24 | $-8.7M | $10.9M | ||
| Q2 24 | $-10.2M | $9.5M | ||
| Q1 24 | $-12.3M | $9.6M |
| Q4 25 | 9.0% | 55.8% | ||
| Q3 25 | -353.4% | 57.5% | ||
| Q2 25 | -292.3% | 62.6% | ||
| Q1 25 | -2921.4% | 52.6% | ||
| Q4 24 | — | 51.0% | ||
| Q3 24 | -264.2% | 52.7% | ||
| Q2 24 | -390.6% | 49.3% | ||
| Q1 24 | -737.8% | 50.0% |
| Q4 25 | 7.2% | 43.9% | ||
| Q3 25 | -346.6% | 43.8% | ||
| Q2 25 | -287.1% | 48.0% | ||
| Q1 25 | -2911.4% | 39.5% | ||
| Q4 24 | — | 40.5% | ||
| Q3 24 | -259.6% | 39.4% | ||
| Q2 24 | -382.7% | 37.1% | ||
| Q1 24 | -719.1% | 37.5% |
| Q4 25 | $0.05 | $1.52 | ||
| Q3 25 | $-0.07 | $1.41 | ||
| Q2 25 | $-0.09 | $1.61 | ||
| Q1 25 | $-0.17 | $1.13 | ||
| Q4 24 | — | $1.13 | ||
| Q3 24 | $-0.17 | $1.07 | ||
| Q2 24 | $-0.20 | $0.92 | ||
| Q1 24 | $-0.25 | $0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.1M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $26.4M | $345.6M |
| Total Assets | $42.2M | $3.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.1M | — | ||
| Q3 25 | $11.7M | — | ||
| Q2 25 | $27.5M | — | ||
| Q1 25 | $13.1M | — | ||
| Q4 24 | $22.5M | — | ||
| Q3 24 | $32.4M | — | ||
| Q2 24 | $30.0M | — | ||
| Q1 24 | $41.0M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $230.8M | ||
| Q3 24 | $1.0M | — | ||
| Q2 24 | $2.0M | — | ||
| Q1 24 | $3.0M | — |
| Q4 25 | $26.4M | $345.6M | ||
| Q3 25 | $13.2M | $334.0M | ||
| Q2 25 | $18.2M | $319.8M | ||
| Q1 25 | $6.6M | $306.1M | ||
| Q4 24 | $17.5M | $295.6M | ||
| Q3 24 | $25.4M | $284.3M | ||
| Q2 24 | $21.6M | $273.4M | ||
| Q1 24 | $30.0M | $266.8M |
| Q4 25 | $42.2M | $3.0B | ||
| Q3 25 | $31.6M | $2.9B | ||
| Q2 25 | $40.7M | $2.9B | ||
| Q1 25 | $22.3M | $2.8B | ||
| Q4 24 | $32.2M | $2.7B | ||
| Q3 24 | $44.8M | $2.6B | ||
| Q2 24 | $42.3M | $2.6B | ||
| Q1 24 | $54.0M | $2.6B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.78× | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.09× | — | ||
| Q1 24 | 0.10× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $44.9M |
| Free Cash FlowOCF − Capex | — | $44.3M |
| FCF MarginFCF / Revenue | — | 125.7% |
| Capex IntensityCapex / Revenue | 0.0% | 1.6% |
| Cash ConversionOCF / Net Profit | -0.68× | 2.90× |
| TTM Free Cash FlowTrailing 4 quarters | — | $81.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.1M | $44.9M | ||
| Q3 25 | $-9.0M | $45.5M | ||
| Q2 25 | $-3.4M | $-25.3M | ||
| Q1 25 | $-8.2M | $17.9M | ||
| Q4 24 | $-36.3M | $48.0M | ||
| Q3 24 | $-7.5M | $17.7M | ||
| Q2 24 | $-10.0M | $-8.4M | ||
| Q1 24 | $-9.8M | $15.8M |
| Q4 25 | — | $44.3M | ||
| Q3 25 | — | $45.3M | ||
| Q2 25 | $-3.4M | $-25.5M | ||
| Q1 25 | $-8.3M | $17.6M | ||
| Q4 24 | $-36.4M | $47.3M | ||
| Q3 24 | $-7.5M | $17.5M | ||
| Q2 24 | $-10.0M | $-8.6M | ||
| Q1 24 | $-9.8M | $15.7M |
| Q4 25 | — | 125.7% | ||
| Q3 25 | — | 138.1% | ||
| Q2 25 | -116.5% | -74.2% | ||
| Q1 25 | -1976.7% | 59.9% | ||
| Q4 24 | -2309.3% | 166.5% | ||
| Q3 24 | -225.7% | 63.3% | ||
| Q2 24 | -376.2% | -33.7% | ||
| Q1 24 | -573.0% | 61.4% |
| Q4 25 | 0.0% | 1.6% | ||
| Q3 25 | 0.0% | 0.7% | ||
| Q2 25 | 0.9% | 0.5% | ||
| Q1 25 | 35.6% | 1.0% | ||
| Q4 24 | 4.2% | 2.4% | ||
| Q3 24 | 0.0% | 0.5% | ||
| Q2 24 | 0.4% | 0.5% | ||
| Q1 24 | 3.2% | 0.3% |
| Q4 25 | -0.68× | 2.90× | ||
| Q3 25 | — | 3.16× | ||
| Q2 25 | — | -1.54× | ||
| Q1 25 | — | 1.54× | ||
| Q4 24 | — | 4.17× | ||
| Q3 24 | — | 1.62× | ||
| Q2 24 | — | -0.89× | ||
| Q1 24 | — | 1.64× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
UNTY
Segment breakdown not available.
